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Abstract  
  
The adoption of new medical technologies is argued to be a major contributory factor to the 
rising cost of health care although there is little empirical work devoted to exploring the 
mechanism of how this process works. This study builds on recent research by Cutler and 
Huckman to establish the degree to which a new technology, percutaneous transluminal 
coronary angioplasty (PTCA), substitutes for an older one (Cutler, D. and Huckman, R., 2003, 
Technological development and medical productivity: the diffusion of angioplasty in New 
York state, Journal of Health Economics, 22, 187-217). Using patient specific data over a 15-
year follow-up period the mortality and morbidity impacts of PTCA relative to coronary artery 
by-pass grafting (CABG) are established. In considering the substitution process, hospital 
level data and control for medical management of CHD improves on the empirical 
specification suggested by the earlier research and the analysis explicitly controls for the 
endogeneity problems in estimating the process of substituting one hospital technology for 
another. Such improvements give robust estimates of the degree to which PTCA has 
substituted for CABG, as opposed to expanding surgical treatment to the potential patient 
population. Thus PTCA, although acting to reduce treatment costs through the process of 
substitution for the more expensive procedure is shown to increase overall costs through 
increasing the potential patient population that could be treated for CHD with surgery.  
  
JEL classification: I1, O3  
  
Keywords: Technological change, Medical productivity  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Introduction  
  
Advances in medical technologies generally expand what is possible and thus lead to 
increasing demand and supply of health care. The adoption of new medical technologies has 
long been argued to be a contributory factor to the rising cost of health care in developed 
countries around the world (Cutler & McClellan 1998; Cutler, McClellan, & Newhouse 1999; 
Newhouse 2002; Weisbrod 1991). There is little empirical work devoted to exploring the 
mechanism of how this process works however, with the majority of such studies focused on 
technology diffusion in the USA. Recently, in one of the rare quantitative papers to address 
this issue, Cutler and Huckman (2003) provided evidence on the impact that the diffusion of a 
specific surgical procedure for coronary heart disease, percutaneous transluminal coronary 
angioplasty (PTCA), had on treatment productivity in New York State. This is an interesting 
case as PTCA is generally considered a potential substitute for the more expensive surgical 
procedure, coronary artery by-pass grafting (CABG). Given that lower unit costs are 
associated with PTCA as compared to CABG it might be expected that total health care costs, 
or at least their rate of growth, would fall in this disease area. However as Cutler and 
Huckman (2003) (hereafter CH) show, while PTCA does act as a substitute for CABG for 
many patients, it also leads to treatment expansion as less severely ill patients are treated with 
the new technology. The impact is therefore to increase overall health care costs even though 
there is a process of substitution at work.  
  
The aim of this paper is to revisit the empirical relationship between PTCA and CABG for a 
number of reasons. First, as CH note it is interesting to consider whether a similar pattern of 
diffusion exists in other health care environments to test the robustness of their findings. The 
data presented here relate to the UK where, through on-going collaborative research of trends, 
it has been established that the regulatory environment tends to lead to a different pattern of 
diffusion for these two technologies across a number of countries (Tech Investigators, 2001). 
In general, possibly reflecting stricter budgetary constraints and an associated greater 
regulatory control of new technology, the UK has had slower and lower up-take rates of both 
CABG and PTCA than the USA generally. The standardised rate of CABG for example 
within one year of admission for acute myocardial infarction (AMI), controlling for country 
specific demographic differences, was under 5% in the UK in 1998 compared to around 20% 
in the USA. The rate of PTCA one day after admission for AMI was less than 4% in the UK 
and, reflecting a more aggressive use of this technology, approximately 11% in the USA in 
1998. Even acknowledging CH’s observation that their data from New York state may differ 
from other states in the USA, the differences between the UK and the USA are of an order of 
magnitude that deserves an assessment of whether the relationship exposed between PTCA 
and CABG in the USA holds in other health care systems.[1] If there is a different 
relationship this will begin to give understanding of any different diffusion mechanisms at 
work across two major health care systems and inform debate over differences in expenditure 
rates across health care systems.  
                                                
  
Secondly, in the empirical specification used as part of their overall assessment of PTCA’s 
productivity impact directed at quantifying the degree of substitutability between PTCA and 
CABG, CH acknowledge that there is inherent bias imbedded in their regression coefficients 
as unobservable factors may be correlated with the CABG and PTCA rates. As an example 
they cite varying rates of medical management for CHD across different localities which they 
can not control for due to data constraints. They argue that as their analysis of substitutability 
relies on examination of the change in the specific coefficient of interest over time, under the 
assumption that the bias is constant over time, their analysis is unaffected. While this may be 
true the assumption of constant bias is crucial to their analysis. As the authors point out, their 
analysis essentially assumes that “the unobservables have the same impact on technology 
utilization over time” (op.cite., p192). This implies that any unaccounted change in medical 
practice and productivity, for instance through changes in medical management arising from 
drug therapy or in medical preferences, has no differential impact on their estimates over the 
18 years of their analysis. As described below, in this paper the econometric model will use 
hospital level data and control for medical management of CHD, proxied by statins 
prescriptions, improving the empirical specification. Further, the parameters of the 
substitution process are estimated by instrumental variables, thus explicitly controlling for the 
endogeneity bias and avoiding a constant bias assumption to interpret the parameter estimates.  
   
Thirdly, as part of their analysis of the productivity impact of the newer technology CH also 
consider the differential effect that PTCA has on health outcomes as compared to CABG. This 
assessment is limited, however, by the fact that their data only allows estimation of the impact 
PTCA has on within hospital mortality over a constrained time period and does not allow 
inspection of long-term outcomes or morbidity data measured, for example, through hospital 
re-admissions. The data used here incorporates long-term follow-up and therefore allows a 
 
1 The rates in New York state are acknowledged by CH (op.cite., p212) to be low compared to other USA states.   
more extensive examination of this relationship.   
  
As has been documented by the TECH Investigators (2000) both CABG and PTCA have 
diffused differently across different health care systems. Three basic patterns are discernible. 
The first, characterised by the USA, is one of early start-up and a quick rise in up-take in new 
procedures. The second pattern, characterised by Canada and Australia, involves a later start 
followed by relatively fast up-take. The last pattern, characterised by the Nordic countries and 
the UK, involves later start-up and slower diffusion. From these results it could be inferred 
that the process of substitution across these two procedures might vary markedly across the 
USA and the UK. Consistent with this earlier study, a simple comparison of procedure rates 
per 1000 population suggests that the trend rates were different when comparing absolute 
levels. However the trends were similar in an important aspect. Figure 1 presents the annual 
procedure rates of CABG and PTCA for the UK patient data used in this analysis. The 
procedure rates are expressed as the number of procedures per 1000 population aged 45 and 
over.[2] The relative pattern follows that shown by CH (op. cite. Fig. 1 in CH) almost exactly. 
Up until 1997 the CABG and PTCA rates rise together with the PTCA rate rising faster than 
the CABG rate. After 1997 the rates move in opposite directions.[3] The conclusion from this 
descriptive data follows therefore that of CH - the differing growth rates and general 
movement in opposite direction after 1997 indicates that PTCA, while it may begin to diffuse 
as a complementary procedure, is a growing substitute for CABG over time. The comparison 
between the data used here with that of CH reflects the different absolute diffusion up-take 
rates across these countries already noted in the TECH study (op. cite.), is that the New York 
state rates rise faster for both CABG and PTCA when compared to the UK. First indications 
would suggest therefore that while a similar substitution mechanism may be operating in both 
the USA and the UK the degree of substitution, as dictated by procedure growth rates, may 
well be different.  
   
 
 
                                                 
2 The population figures used to calculate these rates and for the Scottish health board regions are based on the 
Office of Population and Census and Office of National Statistics estimates.  
 
3 The crossover year in the CH data are 1996. Of interest is the slight flattening of up-take in PTCA between 
1992 and 1994 with subsequent growth, probably attributable to the introduction of stents.  
 
Figure1.  
 
  
 
 
 
The paper proceeds as follows. The next section provides some background material, as well 
as describing the data used in the analysis. Section 3 and 4 discuss issues of specification and 
estimation in the analysis of productivity and substitution respectively, together with the 
estimation results. Section 5 concludes. 
   
2. Data  
  
Data were retrieved from the Medical Record Linkage database held by the Information and 
Statistics Division (ISD) of the NHS in Scotland. This database holds linked data on all 
inpatient and day case hospital episodes from 1981 onwards within Scotland – excluding 
psychiatric and maternity admissions. The ISD Medical Record Linkage Database is detailed 
elsewhere (Kendrick and Clarke, 1993). It has been subjected to a number of reviews relating 
to its quality and ability to link hospital episodes (e.g. Kendrick and Clarke, 1993; Hartley and 
Jones, 1996). The database has been found to have a high level of accuracy as assessed by an 
internal audit of one per cent of the hospital returns annually. The accuracy of the linkage 
system is around 99 per cent overall, while reviews of individual diagnostic categories and 
surgical procedures returns an accuracy of 90 per cent and 94 per cent respectively.  
Moreover, the demographics of the Scottish population are advantageous as the population is 
stable and has low levels of annual migration. The recorded patient level linked data include 
the patient’s age and sex, disease classification and co-morbidity data as based on ICD-9 and 
ICD-10 diagnostic codes, length of stay, operative procedures performed based on the UK 
Office of Population Censuses and Surveys (OPCS, 1997) surgical and procedure  codes 
(OPCS-3 and OPCS-4), whether the hospital admission was elective or emergency and 
discharge information.   
  
The data used in this analysis relate to the linked patient level hospital records for individuals 
who had either a PTCA or a CABG performed within the Scottish region of the UK National 
Health Service (NHS), over the period 1989 to 2003. The start date for this analysis was 
dictated by the fact that data retrieval were based on OPCS surgical and procedure codes and 
PTCA was only assigned such a code in 1989 as it was at that time a new procedure. All 
coronary heart disease (CHD) events were therefore retrieved for the years 1989-2003 and the 
sub-set of patients who had either PTCA or CABG identified. All such individual patient 
records were used, as discussed in more detail below, to analyse the impact that PTCA had on 
long-term health outcomes over a total patient population of 58,842.  
  
For the analysis of the potential substitution of PTCA for CABG the focus is on the hospital 
level. Hospital records, the appropriate level of decision-making in analyzing the up-take of 
new surgical technology, were confined to those hospitals that were the main providers of 
CABG and PTCA procedure within this NHS region. This gave a panel of 4 major hospitals 
over 11 years for the analysis of substitution between the two procedures. Data were also 
retrieved from ISD on prescribing patterns for statins by health board region and the 
calculated prescribing rate for the health boards was applied to individual hospitals[4] as a 
proxy for the level of medical management of CHD, and taken to be a substitute (at the 
margin) for surgical intervention. This allows control for a major unobservable factor noted by 
CH (op. cite.) in their analysis. These prescribing data were only available from 1992 onwards 
which is why the analysis of substitution between the two procedures is restricted to an 11-
year period. Demographic information for the hospital catchment’s area was based on the 
relevant health board population data which was gained from the UK Office of Population and 
Census and Office of National Statistics (www.statistics.gov.uk).  
  
3. Analysis of PTCA impact on health outcome  
  
Following CH the analysis here first considers the impact on health outcome for those 
individuals receiving either PTCA or CABG. Three measures of health outcome are proposed; 
                                                 
4 The overwhelming majority of Scottish health boards only have one hospital represented in the sample. 
in-hospital mortality, any mortality recorded over the (maximum) follow-up period of 15 
years and a combined hospital readmission and mortality outcome measure. The latter is taken 
as an indicator of the impact of PTCA on both mortality and morbidity. Two basic models are 
analysed. First, a logistic regression is undertaken with the dependent variable defined as 
either in-hospital mortality or long-term mortality defined as observed mortality over the 15-
year period of follow-up. Proxying both dependent variable definitions by MORTi  the 
regression model is of the form:  
  
                   
(1)  
where  is an indicator variable (one for received PTCA and zero for received CABG), this 
indicator is then interacted with three-yearly time period indicators which captures any trend 
improvement in the performance of PTCA relative to CABG with respect to outcome. These 
year interactions are estimated relative to the initial data period of 1989-1991. Finally a vector 
of control variables is included that includes year dummies, hospital dummies, age, the 
diagnosis  on presentation for the initial procedure, (coded 1 if AMI; 2 if ischaemic heart 
disease; 3 if stroke, and 4 otherwise) and further dummy variables indicating the presence or 
absence of co-morbidities and whether or not the admission was an elective or emergency.   
  
Given that PTCA and CABG affect both mortality and morbidity an analysis was also 
undertaken allowing for multiple outcome measures; multiple end-points. As well as 
considering mortality within the period of follow-up, counts of hospital readmission based on 
three separate groupings of one, two or three or more readmissions over the 15-year period of 
follow-up, taken as indicators of morbidity, were estimated through a competing risk duration 
model. While it may be argued that unobserved heterogeneity is minimised across patients, 
given selection criteria for the use of these procedures, it is possible that it remains an issue. A 
frailty model was therefore specified. In fact a shared frailty model was proposed given that it 
is unreasonable to assume that the probability of any given outcome was statistically 
independent of any other for any given individual patient. If no account were taken of this 
correlation the underlying hazard rate being modelled would be underestimated. For 
estimation purposes an accelerated failure time model incorporating shared frailties across 
individuals for the pre-defined health outcomes was specified to have a lognormal survival 
function.  
  
Time (t) to one of the four pre-specified endpoints (k) defines the probability of exit to one of 
the k multiple destinations and is dependent on the hazard function to destination k, for the 
cluster of patients, i, treated at hospital j, which is given as   . The probability of 
exit to destination k is therefore given as:  
  
   
  
where the first term on the right hand side are the transition intensities based on the hazard 
function and the second term is the survival function to at least time t. Unobserved 
heterogeneity is allowed for by introducing a frailty as an unobserved multiplicative effect on 
the hazard function, which is clustered around the index variable i. The distribution function 
of the unobservable heterogeneity over the population is specified as Inverse Gaussian. Finally 
the unobservable heterogeneity is assumed to be shared across individuals when these 
individuals face the competing risks of attaining the various end-points. The confounding 
variables, the x
ij
, are the same as used in the logistic regressions. This specification leads to a 
likelihood function which estimates the hazard function for each of the end-points for each 
individual relative to a baseline hazard for the population which takes account of unobserved 
heterogeneity constrained to be similar for each individual even when facing different end-
points. The baseline hazard is assumed to be log-normal.
 5
  With these constraints the 
likelihood function simultaneously estimates the parameter coefficients, β, and the ancillary 
parameters. It is these β coefficients which are of interest, and in particular the coefficient on 
whether or not PTCA was performed as the sign will indicate whether receiving PTCA 
reduced the probability of reaching one of the multiple end-points: death or 1, 2, and 3 or 
more hospital re-admissions.  
  
Table 1 presents the results of the patient level analysis measuring the impact of PTCA on 
health outcomes. The first two equations relate to the logistic regressions using in-hospital 
mortality and any mortality recorded within the 15-year follow-up period as dependent 
variables. The third equation presents the results of the competing risks model described 
above.   
  
Table 1. Results of PTCA on health outcomes  
  Logistic:   
In hospital 
deaths  
Logistic:  
All 
deaths  
  
Competing risk:   
All deaths, 1, 2 & 3 or more hospital 
re-admissions  
  Coeff.  
(s.e.)  
Coeff.  
(s.e.)  
Coeff.  
(s.e.)  
Received PTCA  -1.22**  
(0.031)  
-0.443** 
(0.072)  
-0.358**  
(0.016)  
Age  -4.275**  
(1.227)  
-4.783** 
(2.603)  
-0.005 **  
(0.0001)  
Age squared  9.212**  
(0.976)  
8.982**  
(1.966)  
  
Elective admission  -0.573**  
(0.041)  
-0.121** 
(0.076)  
0.470**  
(0.023)  
Type of CHD/CVD  0.224**  
(0.019)  
0.389**  
(0.032)  
-0.189**  
(0.012)  
Presence of co-
morbidity  
0.509**  
(0.029)  
1.075**  
(0.072)  
-0.3324**  
(0.016)  
Constant  1.478**  
(0.928)  
0.508  
(1.231)  
7.0695**  
(0.441)  
        
Year effects  Yes  Yes  Yes  
Hospital effects  Yes  Yes  Yes  
        
Pseudo  R
2
 0.121  0.171    
Log likelihood  -23163.59  -6806.28 -307105.66  
# observations  58842  58842  58826  
 
 Notes: the Age variable has been re-scaled, and the age squared term was not included in the competing risk analysis.  
** significant at 1% level  
 
The results of all three equations confirm the CH finding, as the coefficient on the PTCA 
indicator is negative and highly significant in each case, that patients who received PTCA are 
less likely to die in hospital or over the follow-up period than those receiving CABG. The 
competing risks model infers that morbidity, as modelled through multiple hospital re-
admissions, is also likely to be improved in those receiving PTCA rather than CABG. Indeed 
the results tend to support the suspicion noted by CH that given their data limitations, 
particularly that the definition of mortality in their analysis is confined to in-hospital mortality 
which is rarely associated with PTCA or CABG (generally post-operative death rates are less 
than 2% even for CABG), their regression results should only be taken as indicative of the 
impact.[5] The signs on all the other coefficients are consistent across the logistic equations 
with the probability of death increasing with age, emergency admissions and the presence of 
co-morbidity. The coefficient signs in the competing risk model are more complex to interpret 
as the effect relates not only death but also to re-admission rates.  The negative sign on the 
type of CHD/CVD points to an association of higher re-admission rates for individuals who 
initially suffered an AMI or IHD rather than stroke. Moreover the positive sign on the type of 
admission may also merely be picking up higher re-admission rates of survivors, proxied by 
initial elective rather than emergency admissions, over time. This may also explain the 
negative sign on the co-morbidity variable. Notwithstanding the more complex interpretation 
of these coefficients in the competing risks model, all results are highly supportive of PTCA 
leading to improved outcomes over CABG. 
 
 
4. Analysis of the substitution of PTCA for CABG  
  
To formalise their analysis of the degree to which PTCA has substituted for CABG, CH 
specify the following model using county as the unit of analysis:  
  
       
  
where the dependent variable, the CABG rate per 1000 population aged 45 and over, is 
regressed against county fixed effects (αi),  year fixed effects, (δt)  the PTCA rate per 1000 
population aged 45 and over, an interaction term of the PTCA rate per 1000 population aged 
45 and over with  st  , a vector of indicators of 3-year periods, and a vector of demographic 
controls xit , including the percentage of a counties population that falls into each of three age 
categories: under 45, 45-64 and over 65, and the rate of total hospital discharges per 100,000 
                                                 
5 The lognormal survival function is represented by a hazard that first increases from zero and then falls towards 
zero and parameterised as  . The Inverse Gaussian distribution is commonly 
applied to model unobserved heterogeneity in such models because of it’s analytical tractability. Fuller 
discussion of frailty models is found in Lancaster (1990, ch. 6)  
 
population to control for shifts in overall hospitalisation rate. They also include the different 
form of payment mechanism (Medicare, Medicaid and HMO), which are not relevant to this 
analysis. [6]  
  
To initiate the analysis performed here the same specification is used with subtle differences. 
As noted above, instead of the county being the level of analysis, the hospital is used as the 
unit of observation in this study. This reduces sample size but better reflects the level at which 
decisions are made concerning the substitution of PTCA for CABG. The total hospital 
discharge rate is also specified at the hospital rather than county level. All population rates are 
defined with respect to the relevant Health Board population level.[7] 
 
In the CH analysis, the coefficients of greatest interest are represented by the vector (βS-β1). 
By using time-varying coefficients the degree of substitution between the procedures is 
allowed to change over time as PTCA matures. CH consider this specification in levels and, 
through differencing the variables CABG, PTCA and total discharges only, also with respect 
to trends in the growth rate. The latter is referred to by CH as a changes specification. CH note 
that unobservable factors εit  will be correlated with both CABG and PTCA and therefore the 
OLS estimator for β1  and the βS  will be biased and consequently the value of substitution for 
any given period. By assuming that the bias in any given period is constant, they argue that 
(β1-βS) can be estimated without bias. By then assuming that β1=0 , CH obtain the substitution 
rates over time.  
 
We endeavour to deal with the endogeneity problem in two ways. First, in the specification 
considered here an important unobservable, namely the medical management of CHD, is 
controlled for. This is done through the inclusion of a variable which quantifies the proportion 
of the relevant Health Board population who were prescribed statins to proxy the use of 
medical management within the at risk population.  
  
Secondly, we estimate the parameter S   directly taking account of the endogeneity of  by the 
                                                 
6 In fact CH do not use the results in their main productivity calculations but rely on results from randomised 
clinical trials which compare the two procedures.  
 
7 There are 15 Health Boards in Scotland, nine have one hospital per Health Board; four have two; and one have 
five and three hospitals respectively. With very little cross-Board flows for these procedures, the Health Board 
population therefore represents a relatively good proxy for each hospitals population draw. 
method of Instrumental Variables (IV). As there are two sources of endogeneity, the 
correlation between PTCAi and the hospital effects αi  and the time varying unobservables εit , 
we first take first differences of model (2) which eliminates the hospital effects αi :  
   
  
 .              
(3)  
            
As 
itPop
PTCA 



  will be correlated with the unobservables εit , we instrument the differences 
 st
Pop
PTCA
it



   by lagged levels  st
Pop
PTCA
it



 , along the lines of the standard 
panel data estimator of Arellano and Bond (1991). We estimate this model by Two-Stage 
Least Squares (2SLS), resulting in a consistent estimator for S   itself, i.e. no longer in 
deviation of β1.  
  
The initial results relating to the process of PTCA substitution for CABG are presented in 
Table 2 and replicate the CH model in levels, (model (2) above), but include the influence of 
the potentially important missing proxy relating to medical management (proxied through the 
level of statin prescription). The first two columns present the OLS estimation results with and 
without fixed hospital effects. The final column is specified in differences. The results for the 
fixed effects specification are remarkably similar to those of CH, as presented in their Table 2 
(op. cit. CH p.201)). Using their assumption that the bias is constant over time and that 
substitution away from CABG accounts for none of the increased PTCA volume in the 1993-
1995 period, we also find a substitution rate of around 40-50% by the end of the period. 
Clearly, the quite large positive estimate for the 1993-1995 period,  in the fixed effects 
specification, may be due to endogeneity bias under these assumptions,  and the 
inclusion of the number of statins prescriptions perhaps does not control enough for this 
endogeneity problem.[
58.0ˆ1 
8] 
 
 
                                                 
8 Interestingly, when the Statins variable is excluded from the fixed effects regression, the coefficients (βs) are 
not individually and jointly significantly different from zero. 
Table 2. OLS estimation of the substitution impact of PTCA on CABG  
CABG   Levels  Fixed effects First Differences  
  Coeff  
(rob s.e.)  
Coeff  
(rob s.e.)  
Coeff  
(rob s.e.)  
        
PTCA rate (β1) 0.1521  
(0.421)  
0.5756**  
(0.2254)  
0.2817  
(0.3212)  
1995-1997 (β2-β1) -0.1099  
(0.0727)  
-0.1761  
(0.1350)  
-.2806   
(0.4204)  
1998-2000 (β3-β1) -0.3622  
(0.4710)  
-0.4029  
(0.3224)  
-0.009  
(0.4988)  
2001-2003 (β4-β1) -0.0246  
(0.0789)  
-0.5090*  
(0.2611)  
-0.4582  
(0.4018)  
Statins  -0.0157  
(0.0133)  
-0.0636**  
(0.0267)  
-0.0358  
(0.0358)  
Discharge per 1,000 population  0.0064  
(0.0064)  
0.0045  
(0.0103)  
-0.106**  
(0.0122)  
% population<45 years old  -0.1088  
(0.1146)  
-0.2756**  
(0.1445)  
-0.1968  
(0.1895)  
% Pop. 45-64  0.1829** 
(0.1046)  
-0.1366  
(0.2245)  
-0.9130**  
(0.2337)  
        
Year effects  Yes  Yes  Yes  
Hospital effects  No  Yes  No  
        
# observations  44  44  44  
# hospitals  4  4  4  
 
*
 significant at 5% level;; 
**
 significant at 1% level  
 
 
Table 3 presents the results of the instrumental variables estimation procedure for  model (3) 
in first differences. As can be seen for the full model with minimal instruments, reported in 
the first column of results, the overall level of significance is poor for the PTCA variables and 
for the variable proxying medical management; although the sign on this latter variable is in 
line with a priori expectations. To gain more parsimony the statins variable and age profile 
variables were dropped as regessors but retained as instruments, retaining their effect albeit 
indirectly. The estimation results are presented in the second column of Table 3. The third 
results column further places some exclusion restriction on the year effects. Indeed with 
restrictions placed on the year effects the model becomes relatively well-behaved, with the 
instruments validity not rejected as indicated by the results of the J-test. Again, we find a 
significantly positive effect for the 1992-1994 period, as in the fixed effects model presented 
in Table 2, but now the results suggest that there is strong substitutability of PTCA for CABG 
by the end of the period, without having to make any assumptions about the constancy of bias 
and that there is no substitution in the first period.[9] This is consistent with the TECH (2000) 
results which show a much slower pattern of up-take of PTCA in the UK compared to the 
USA. This conservative pattern of up-take in the UK is consistent with PTCA initially being 
introduced in a complementary fashion in the UK, at a time when, according to the results of 
CH it was already acting as a strong substitute for CABG in the USA. However, reflecting the 
basic trends shown in Figure 1 above, PTCA begins to be a substitute procedure for CABG in 
the mid-1990s within the UK, although not strongly so until the last period of analysis. 
Moreover this degree of substitution is around the level estimated for CH with respect to their 
final period (the late 1990s). In this respect the findings here, that PTCA substitutes for CABG 
by 30%, support their hypothesis that PTCA does substitute for CABG at the margin by 
around 25 to 35% depending on the specification used by CH. This further supports the notion 
that, although PTCA is effective and less expensive than CABG, through expanding the 
potential treatment population overall health care costs are increased.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
9 The coefficients β1,… β4  are jointly significant with a p-value of 0.0000. 
Table 3. IV estimation of the substitution impact of PTCA on CABG  
CABG   First Differenced Models  
  Coeff  
(rob s.e.)  
Coeff  
(rob s.e.)  
Coeff  
(rob s.e.)  
PTCA rate        
1992-1994  
(β1) 
0.3501**  
(0.1015)  
0.3704**  
(0.0887)  
0.4243**  
(0.0674)  
1995-1997 
  (β2) 
-1.1187  
(1.3646)  
-0.0783  
(0.2275)  
-0.1638  
(0.1131)  
1998-2000  
 (β3) 
0.9580**  
(0.3620)  
-0.0985  
(0.3934)  
0.1108  
(0.4233)  
2001-2003  
(β4) 
-0.4839  
(0.3835)  
-0.3532**  
(0.1777)  
-0.2988**  
(0.0773)  
Statins  -0.0265  
(0.0472)  
    
Discharge per 1,000 
population  
-0.0099  
(0.0089)  
-0.0181**  
(0.0083)  
-0.0159**  
(0.007)  
% population<45 years 
old  
-0.0155  
(0.3001)  
    
% Pop. 45-64  0.5275  
(0.5219)  
    
Year effects  Yes  Yes  Restricted  
        
# observations  44  44  44  
# hospitals  4  4  4  
        
J-test: p-value (dof)  0.239 (4)  0.4 (7)  0.728 (7)  
        
Instruments   
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5. Conclusions  
  
This study has replicated the approach adopted by Cutler and Huckman (2003) to establish the 
degree to which new technology, specifically PTCA, substitutes for an older one, in this case 
CABG in a health care system which is known to have generally low levels of technology 
diffusion. Using patient specific data over a 15-year follow-up period the mortality and 
morbidity impacts of PTCA relative to CABG are clearly established. In considering the 
substitution process using hospital level data and using estimation methods to control for 
endogeneity an improved empirical specification is suggested in comparison to earlier work. 
Such improvements quantify the degree to which PTCA has substituted for CABG, as 
opposed to expanding surgical treatment to the potential patient population. It has been shown, 
as represented by the data here that by the end of the period of study the UK witnessed 
degrees of substitution between PTCA for CABG that were of the same magnitude witnessed 
in the U.S. study. However caution must be exercised when making such direct comparisons 
on the process of substitution across the CH analysis and this analysis as slightly different 
time periods are analysed. CH consider 1982 through to 2000 and cover the early 
establishment of PTCA, while this study considers 1992 through to 2003 and therefore relates 
to a more mature period of up-take. Notwithstanding this caveat the orders of magnitude in the 
estimated value of substitution imply that the technology diffusion process is similar in the 
two countries. The international comparison of operative procedure rates of up-take in this 
treatment area analysed by the TECH Investigators (2001) concluded that the USA was 
characterised by early-start and quick up-take, while the UK was characterised by late-start 
and slow up-take. This current analysis would suggest that, if direct comparison is made to the 
CH results, consistent with this earlier TECH finding the UK catches up with US levels of 
substitution with some lag.  
  
While specific productivity calculations are not pursued here clearly more work at this level of 
investigation is required. Further work to establish the degree of substitution between these 
technologies in other countries, or applying a similar analysis to other technologies would be 
of interest. More fundamentally establishing the impact that the regulatory environment and 
the payment system has on the diffusion pattern of new health care technology is vital to the 
understanding of the mechanisms through which such technology impacts on health care costs 
generally.   
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